Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US7829534B2 · kind B2 · utility
10Cited by
25References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 29, 2007 |
| Grant date | Nov 9, 2010 |
| Priority date | — |
| Expiry date | Nov 7, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.